• mutants develop hyperplastic alveolar nodules (J:132088)

• 100% of mutants develop invasive mammary cancer

• some cancers are Esr1-negative while others are Esr1-positive

• mutants develop mammary gland preneoplasia

• some preneoplasia are Esr1-negative while others are Esr1-positive

• mutants develop hyperplastic alveolar nodules (J:132088)

• when 14 week old males are removed from doxycycline administration for 50 days, seminal vesicles show a decrease in mass compared to controls (J:78639)

• when 14 week old males are removed from doxycycline administration for 50 days, seminal vesicles show a decrease in mass compared to controls (J:78639)

• when 14 week old males are removed from doxycycline administration for 50 days, epididymis weight is decreased compared to controls (J:78639)

• when 14 week old males are removed from doxycycline administration for 50 days, vas deferens weight is decreased compared to controls (J:78639)

• females raised on doxycycline to block expression of Esr1 exhibit a decrease in the number of days in estrus when the doxycycline is removed and Esr1 is expressed, however overall cycle length is no different from controls (J:78639)

• mutants without doxycycline (expressing Esr1) exhibit a 15% reduction in litter size compared to mutants receiving doxycycline

• exposure to exogenous estrogen does not increase or change the prevalence of ductal abnormalities, proliferative disease or ductal carcinoma in situ (J:96383)

• neither hyperplasia nor ductal carcinoma in situ regress within a 2-week period following doxycycline treatment in 4 month old mutants (J:96383)

• ovariectomized mice do not show ductal hyperplasia, ductal carcinoma in situ or other ductal abnormalities (J:96383)

• mutants which were treated with doxycycline at 3 weeks of age to inhibit Esr1 expression exhibit normal mammary gland development (J:96383)

• at 4 months of age, mutants show abnormal mammary ductal structures, including lateral budding, dilated ducts, and abnormal branching (J:96383)

• at 4 months of age, mutants show lateral budding and abnormal branching of mammary gland ducts (J:96383)

• 33% and 36% of mutants at 2 and 4 months of age, respectively, show ductal hyperplasia (J:96383)

• rates of mammary epithelial cell proliferation are increased compared to controls (J:96383)

• 52% of mutants at 4 months of age show lobular hyperplasia (J:96383)

• 12 month old mice display hyperplastic alveolar nodules with increased frequency of mitotic figures within the hyperplasias (J:96383)

• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ

• exposure to exogenous estrogen does not increase or change the prevalence of ductal abnormalities, proliferative disease or ductal carcinoma in situ (J:96383)

• neither hyperplasia nor ductal carcinoma in situ regress within a 2-week period following doxycycline treatment in 4 month old mutants (J:96383)

• ovariectomized mice do not show ductal hyperplasia, ductal carcinoma in situ or other ductal abnormalities (J:96383)

• mutants which were treated with doxycycline at 3 weeks of age to inhibit Esr1 expression exhibit normal mammary gland development (J:96383)

• at 4 months of age, mutants show abnormal mammary ductal structures, including lateral budding, dilated ducts, and abnormal branching (J:96383)

• at 4 months of age, mutants show lateral budding and abnormal branching of mammary gland ducts (J:96383)

• 33% and 36% of mutants at 2 and 4 months of age, respectively, show ductal hyperplasia (J:96383)

• rates of mammary epithelial cell proliferation are increased compared to controls (J:96383)

• 52% of mutants at 4 months of age show lobular hyperplasia (J:96383)

• 12 month old mice display hyperplastic alveolar nodules with increased frequency of mitotic figures within the hyperplasias (J:96383)